Axogen (AXGN) Q1 2023: Core Accounts Up 23%, Deepening Nerve Repair Penetration

May 9, 2023 | By EarningsIQ Research

Axogen’s Q1 saw core account growth accelerate, driving deeper adoption of nerve repair solutions and supporting the company’s innovation-led strategy. New product launches and robust clinical data are strengthening Axogen’s position in both trauma and planned nerve repair, while operational discipline is moving the business closer to profitability. With a new facility coming online and regulatory milestones on track, Axogen is poised for further penetration in under-addressed nerve injury segments.

Summary

• Core Account Penetration: Deepening adoption in core accounts is unlocking higher-value procedures and planned case growth.
• Innovation Pipeline Momentum: New product launches and clinical evidence are expanding Axogen’s reach in nerve protection and breast neurotization.
• Operational Leverage Building: Scaling sales productivity and prudent cost management are narrowing losses and supporting a path to breakeven.

Business Overview

Axogen develops and markets surgical solutions for peripheral nerve repair, addressing traumatic injuries and planned procedures in extremity, breast reconstruction, oral and maxillofacial (OMF), and pain management. The company’s revenue is primarily driven by its Avance Nerve Graft, allograft nerve repair product, supported by a portfolio including AxiGuard, nerve protector, and connectors. Axogen’s business model leverages a direct sales force, surgeon education, and clinical evidence to drive adoption in hospitals and surgical centers, with a focus on expanding both account penetration and the breadth of applications for its products.

Performance Analysis

Axogen delivered 18% year-over-year revenue growth in Q1, marking its third consecutive quarter of high-teens expansion. This growth was fueled by a 10% increase in unit volume and 4% gains each from pricing and product mix, reflecting both increased procedure volume and a shift toward higher-value, longer Avance grafts. Core accounts, defined as those with over $100,000 in trailing 12-month revenue, rose 23% year-over-year to 350 and now represent approximately 60% of total revenue, underscoring Axogen’s strategy of deepening penetration in high-value accounts.

Gross margin remained strong at 81.7%, with a slight dip due to product and facility transition, while operating expenses rose just 1%. Sales and marketing spend grew modestly, but as a percentage of revenue, it declined significantly, demonstrating operating leverage. The net loss narrowed both on a GAAP and adjusted basis, and adjusted EBITDA loss was halved year-over-year, signaling progress towards breakeven. Cash burn included seasonal items and investment in the new Dayton processing facility, with normalized capital expenditures expected to decline post-completion.

• Account Concentration Shift: Top 10% of accounts now contribute 35% of revenue, reflecting targeted focus on high-potential customers.
• Product Mix Evolution: Avance Nerve Graft is trending toward 60% of revenue, up from 50%, as longer grafts and complex cases gain share.
• Sales Force Productivity: Direct reps remained stable, but management expects productivity gains as core account penetration and planned case mix increase.

Overall, Axogen’s Q1 performance validates its focus on core accounts, innovation, and commercial execution, while operational discipline is improving the company’s financial profile.

Executive Commentary

Strategic Positioning

1. Core Account Deepening

Axogen’s strategy is centered on expanding the depth of usage within existing high-value accounts, particularly by leveraging surgeon champions to drive broader adoption across teams and specialties. By focusing on core accounts—now 60% of revenue—the company is unlocking more planned procedures and increasing the use of advanced nerve repair algorithms.

2. Product Innovation and Portfolio Expansion

Recent launches such as AxiGuard HA Plus, nerve protector with enhanced gliding properties, and the new implant-based breast neurotization technique are designed to address unmet needs and expand Axogen’s reach within nerve protection and reconstruction. These innovations are not expanding the total addressable market but are deepening penetration and providing premium-priced options for complex cases.

3. Clinical Evidence as a Commercial Lever

Peer-reviewed meta-analyses and cost studies are validating the efficacy and economic parity of allograft over autograft, supporting sales rep efforts to shift surgeon behavior, especially in longer and more complex nerve repairs. This evidence is accelerating adoption curves and enabling Axogen to move beyond early adopters.

4. Sales Force Optimization

Axogen continues to prioritize direct sales over independent agents, particularly in metropolitan areas where training and procedural support can drive higher productivity. Independent agencies now represent just 10% of sales, focused on geographically diffuse trauma cases, while direct reps are being optimized for planned case growth and territory efficiency.

5. Manufacturing and Regulatory Milestones

The new Dayton, Ohio processing facility (APC) is on track to support both capacity growth and regulatory requirements, with the Biologics License Application (BLA) for Avance expected by year-end. A successful BLA would provide 12 years of data exclusivity, enhancing Axogen’s competitive moat against potential biosimilars.

Key Considerations

Q1’s results highlight Axogen’s ability to execute on multiple fronts, from commercial expansion to innovation and operational discipline. The company is actively managing its sales force structure, product mix, and clinical evidence pipeline to drive sustained growth and margin improvement.

Key Considerations:

• Clinical Data Impact: Recent meta-analyses and cost studies are influencing surgeon adoption and expanding applications in trauma and planned cases.
• Facility Transition: The APC facility will temporarily pressure gross margins but is essential for future growth and regulatory compliance.
• Planned vs. Emergent Mix: Shifting toward more planned procedures improves sales rep productivity and revenue predictability.
• Innovation-Driven Penetration: New products like AxiGuard HA Plus are deepening Axogen’s reach in complex nerve protection, not just expanding the TAM.
• Cash Management: Seasonality and facility investment drove Q1 cash burn, but normalized CapEx and improving operating leverage are expected to stabilize the balance sheet.

Risks

Hospital staffing constraints and limited OR capacity remain a headwind to full market normalization, potentially capping near-term procedure volume. Gross margin pressure from facility transition and the risk of regulatory delays for the BLA submission could impact profitability and competitive positioning. Surgeon adoption curves, while improving, still require ongoing education and evidence dissemination, with variability in uptake across regions and specialties.

Forward Outlook

For Q2 2023, Axogen expects:

• Seasonal uptick in trauma procedures as the spring and summer “trauma season” unfolds.
• Continued normalization of elective and planned case volume as hospital environments stabilize.

For full-year 2023, management reiterated guidance:

• Revenue of $154 to $159 million.
• Gross margin to dip temporarily with facility transition, returning to ~80% by Q4.

Management highlighted that core account penetration, new product launches, and ongoing clinical evidence generation are expected to drive growth, while operational discipline will support the path to breakeven.

• Facility completion and BLA submission remain on track.
• Sales force productivity and planned case mix are key levers for continued margin improvement.

Takeaways

Axogen is executing a focused growth strategy by deepening existing account relationships and leveraging innovation to drive procedure mix and margin improvement.

• Core Account Penetration: Growth is increasingly concentrated in high-value accounts, with deeper adoption driving both volume and mix improvements.
• Innovation and Evidence: New products and strong clinical data are enabling Axogen to expand its reach within nerve repair and protection, supporting both commercial and reimbursement efforts.
• Profitability Path: Operational leverage, facility investments, and disciplined expense management are narrowing losses and positioning the company for future profitability as growth normalizes.

Conclusion

Axogen’s Q1 2023 results underscore a business gaining commercial traction and operational discipline, with innovation and clinical validation fueling deeper market penetration. As the company transitions to a new facility and advances regulatory milestones, investors should watch for sustained core account growth and margin recovery as key signals of long-term value creation.

Industry Read-Through

Axogen’s results reinforce several industry trends: The growing importance of clinical evidence in driving adoption for advanced surgical technologies, the value of direct sales models in complex medical device markets, and the critical role of operational discipline during scale-up phases. For the broader medtech and surgical device sector, the shift toward planned procedures and premium-priced innovation—backed by robust data—will be central to post-pandemic growth strategies. Facility investments and regulatory exclusivity are emerging as key competitive differentiators in biologics and graft-based therapies, signaling a rising bar for new entrants in the nerve repair and adjacent markets.

AXGN Health Care Medical Devices Innovation Nerve Repair Clinical Evidence Core Accounts Facility Expansion